Vismodegib is being studied in three separate trials in the pancreatic indication. Each trial being added successively. They continue to expand the trials. IPI, Infinity's drug showed solid evidence of efficacy in earl studies in the same indication with their Hh antagonist. Adding nab-paclitaxel, deteriorates the stroma, adding an Hh does as well, but the addition of the Hh kills the stem cells which, in theory, should be highly beneficial to prevent tumor rebuild.
There are several patient profiles in the Vismodegib studies I have read online. One, in which the patient had a complete response on her liver lesions, and a 51% reduction in her pancreatic tumor after 3 months on the therapy.
There are several articles and commentaries (including the Stand Up To Cancer "dream team" for pancreatic cancer) speaking about Hh combination therapies.
Like I said, I will take my chances that all of the above simply isn't "by chance".
News 
Market Data 
Discover 
AI
